Pricing
  1. US-listed companies
  2. Panbela Therapeutics, Inc.
  3. Financials
  4. Research & development

Panbela Therapeutics, Inc.【PBLA】

Market cap
$63.36K
P/E ratio
SummaryFinancials
Period EndResearch & development (Million USD)YoY (%)
Dec 31, 202321-26.51%
Dec 31, 202228+417.22%
Dec 31, 20215+116.49%
Dec 31, 20203+6.64%
Dec 31, 20192+31.74%
Dec 31, 20182-31.24%
Dec 31, 20173+3.55%
Dec 31, 20163-12.20%
Dec 31, 20153+Infinity%
Dec 31, 20140-100.00%
Dec 31, 20130

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)